8 results about "Metastatic cell" patented technology

Substances and methods are disclosed for reducing or preventing metastatic behaviour in VGSC expressing cancer by the effect of at least reducing the persistent part of the voltage gated sodium channel current without eliminating the transient part. Inhibition of metastatic cell behaviours such as detachability, lateral motility, transverse migration and invasiveness is demonstrated using the known drugs ranolazine and riluzole.

This invention provides a nucleic acid aptamer that targets and binds to the IGF2BP2 protein and its application, belonging to the field of pharmaceutical technology. This invention is the first to design a highly specific nucleic acid aptamer targeting the RNA recognition protein IGF2BP2, obtaining a nucleic acid aptamer that can target and specifically bind to the IGF2BP2 protein (see SEQ ID No. 1-2). This nucleic acid aptamer can effectively inhibit the activity of tumor cells, tumor stem cells, and breast cancer brain metastases, breast cancer lung metastases, breast cancer liver metastases, breast cancer kidney metastases, and breast cancer bone metastases, providing a new drug component for the treatment of malignant and refractory tumors (especially glioblastoma and distant metastatic breast cancer). Furthermore, it was discovered that modification with N6-methyldeoxyadenosine monophosphate can further enhance the specificity of the nucleic acid aptamer and strengthen its efficacy in inhibiting tumor cell activity.

The invention discloses a small-molecule inhibitor ratenshu and application thereof, and belongs to the technical field of biological pharmacy. On the basis of mostly retaining the immunosuppressive activity of triptolide, the small-molecule inhibitor ratenshu disclosed by the invention has the advantages that the toxicity is greatly reduced, the solubility is improved, and the druggability is better. Besides, the small-molecule inhibitor ratenshu is small in side effect and high in targeting performance, the small-molecule compound capable of smoothly passing through the blood-brain barrier can treat or reduce growth of non-small cell lung cancer brain metastatic cells, and the small-molecule inhibitor ratenshu has wide application prospects when being applied to preparation of drugs for treating non-small cell lung cancer brain metastatic growth.

The invention discloses a bionic nano-carrier capable of reversibly regulating and controlling a blood brain barrier and application of the bionic nano-carrier. The bionic nano-carrier is of a core-shell structure, a lecithin surface modified inorganic nano-material serves as a core, a cell membrane of brain metastatic cancer cells coats the surface of the core to serve as a shell, and an A2A adenosine receptor agonist is loaded in a cell membrane coating layer. The blood brain barrier crossing efficiency is further improved; wherein the lecithin surface modified inorganic nano-material is obtained by using an oleic acid modified inorganic nano-material as a matrix and carrying out surface modification through amphiphilic ligand lecithin. The bionic nano-carrier regulates and controls the blood-brain barrier permeability in a reversible mode, the problems that the brain transfer efficiency of a brain metastatic cell membrane bionic carrier through a cell bypass path is limited, potential safety hazards exist in a traditional blood-brain barrier permeability regulation and control open means and the like are solved, and a new strategy is provided for efficient brain delivery.

An example system for cancer metastasis detection and risk prediction includes a cell identification module and a risk prediction module, where the risk prediction module is configured to analyze identified cell types and assess the likelihood of metastasis. An example computer-implemented method includes receiving a sample, identifying cancer metastatic and precursor cell types using a cell identification module, predicting the risk of metastasis occurrence using a risk prediction module, and outputting the timing and location of potential metastasis.

The application belongs to the technical field of biological medicine, discloses application of bone metastasis specific secreted protein DKK3 in early diagnosis of lung cancer bone metastasis, and specifically discloses application of a substance for detecting DKK3 in preparation of a product for diagnosing or early screening of lung cancer bone metastasis. The application discloses the relationship between secreted protein DKK3 expression and lung cancer specific bone metastasis for the first time, and verifies that secreted protein DKK3 is specifically highly expressed in serum samples of lung cancer bone metastasis patients and lung cancer bone metastasis cells, which indicates that secreted protein DKK3 can be used as a new lung cancer bone metastasis diagnostic marker, and can significantly distinguish lung cancer patients with bone metastasis from lung cancer patients with metastasis to other organs and healthy people.

The application relates to the field of biological medicine, in particular to a human renal clear cell carcinoma high-metastasis cell line, which is classified and named as human renal clear cell carcinoma high-metastasis cell 786O-M2-Luc Homo sapiens, and the preservation number is CCTCC No: C2025339. The renal clear cell carcinoma high-metastasis cell line can be applied to constructing a renal clear cell carcinoma high-metastasis cell model or an animal model. The cell line of the application can form a stable orthotopic tumor in an immunodeficient mouse, can cause distant organ metastasis such as lung metastasis, can express a GFP and Luciferase double-reporting system, and is convenient for in-vitro sorting and in-vivo IVIS imaging tracking. The cell line of the application retains the typical renal cell carcinoma characteristics of 786-O cells in vitro, but has stronger proliferation, migration and invasion capacity, and can be used as a tool model for renal cancer metastasis mechanism research and drug screening.